Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
Adrian F. Hernandez, Jacob A. Udell, W. Schuyler Jones, et al.
Circulation (2024) Vol. 149, Iss. 21, pp. 1627-1638
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction
Jacob A. Udell, Mark C. Petrie, W. Schuyler Jones, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 23, pp. 2233-2246
Open Access | Times Cited: 17
Endothelial Protection by Sodium-Glucose Cotransporter 2 Inhibitors: A Literature Review of In Vitro and In Vivo Studies
N Mylonas, Panagiota Nikolaou, Paschalis Karakasis, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7274-7274
Open Access | Times Cited: 17
Where Are We With Treatment and Prevention of Heart Failure in Patients Post–Myocardial Infarction?
Jaclyn Carberry, Guillaume Marquis‐Gravel, Eileen O’Meara, et al.
JACC Heart Failure (2024) Vol. 12, Iss. 7, pp. 1157-1165
Open Access | Times Cited: 11
Growth differentiation factor 15: A biomarker to guide empagliflozin treatment in acute myocardial infarction?
Óscar M. Peiró, Alfredo Bardajı́, Anna Carrasquer, et al.
International Journal of Cardiology (2025), pp. 133167-133167
Closed Access | Times Cited: 1
Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS‐MI): rationale and design
Jaclyn Carberry, Mark C. Petrie, Matthew M.Y. Lee, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 4, pp. 2001-2012
Open Access | Times Cited: 7
Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes
Qing Feng, Moya Wu, Zizhao Mai
Frontiers in Cardiovascular Medicine (2025) Vol. 12
Open Access
Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings
Alessandro Cuttone, Vittorio Cannavò, Rana Abdullah, et al.
Cells (2025) Vol. 14, Iss. 9, pp. 668-668
Open Access
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS‐MI)
Jaclyn Carberry, Mark C. Petrie, Matthew M.Y. Lee, et al.
European Journal of Heart Failure (2024)
Closed Access | Times Cited: 3
Failure to improve cardiac remodelling and outcomes post‐myocardial infarction: Insights from EMPRESS‐MI
Francesco Fioretti, Gregg W. Stone, Javed Butler
European Journal of Heart Failure (2025)
Open Access
Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction
Nicia I. Profili, Roberto Castelli, Roberto Manetti, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 720-720
Open Access
Possibilities of Optimizing Drug Therapy for Myocardial Infarction: a Consensus on the Use of Type 2 Sodium-Glucose Co-Transporter Inhibitors. Conciliation Document of the Expert Group
G. P. Arutyunov, С. К. Кононов, N Novitskii, et al.
Kardiologiia (2025) Vol. 65, Iss. 3, pp. 35-47
Closed Access
Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure
Matteo Armillotta, Francesco Angeli, Pasquale Paolisso, et al.
Pharmacology & Therapeutics (2025) Vol. 270, pp. 108861-108861
Open Access
Temporal trends in heart failure and acute kidney injury-related mortality in the U.S.: a 21-year retrospective analysis of the CDC WONDER database
Rayyan Nabi, M. Humayoun Akhtar, S. P. Rath, et al.
International Urology and Nephrology (2025)
Closed Access
Impact of Sodium-glucose Co-transporter 2 Inhibitors on Cardiovascular Outcomes in Patients with Acute Myocardial Infarction: Systematic Review and Meta-Analysis
Mohammad Akkawi, Prakash Upreti, Ahmad Damlakhy, et al.
The American Journal of the Medical Sciences (2025)
Closed Access
Advances in cardiovascular pharmacotherapy. III. Sodium-glucose cotransport type 2 inhibitors, part 1: efficacy in heart failure and myocardial infarction
Paul S. Pagel, Dustin Hang, Julie K. Freed, et al.
Journal of Cardiothoracic and Vascular Anesthesia (2025)
Closed Access
Empagliflozin: primum inter pares among sodium-glucose cotransporter-2 inhibitors?
Giuseppe Biondi‐Zoccai, Giacomo Frati, Mariangela Peruzzi, et al.
Journal of Cardiovascular Pharmacology (2024) Vol. 84, Iss. 3, pp. 271-275
Closed Access | Times Cited: 1
Empagliflozin in Acute Myocardial Infarction Reduces No-Reflow and Preserves Cardiac Function by Preventing Endothelial Damage
Panagiota Nikolaou, Lara S. F. Konijnenberg, Ioannis V. Kostopoulos, et al.
JACC Basic to Translational Science (2024) Vol. 10, Iss. 1, pp. 43-61
Open Access | Times Cited: 1
Pharmacotherapy of acute ST-elevation myocardial infarction and the pharmacist’s role, part 2: Complications, postrevascularization care, and quality improvement
Sara J. Hyland, Marion E Max, R. Philip Eaton, et al.
American Journal of Health-System Pharmacy (2024)
Open Access | Times Cited: 1
Sodium–glucose cotransporter 2 inhibitors in acute and chronic coronary syndrome with and without heart failure
Eugenia Cisneros‐Barroso, Xavier Rosselló
European Journal of Heart Failure (2024) Vol. 26, Iss. 7, pp. 1606-1607
Closed Access
Weekly Journal Scan: sodium/glucose cotransporter 2 inhibition after myocardial infarction still in the grey area
Giovanna Liuzzo, Carlo Patrono
European Heart Journal (2024) Vol. 45, Iss. 27, pp. 2360-2361
Open Access
News in cardiovascular pharmacotherapy from the ACC.24 Meeting
Ricardo Caballero, Eva Delpón, Juan Tamargo
European Heart Journal - Cardiovascular Pharmacotherapy (2024) Vol. 10, Iss. 4, pp. 272-277
Open Access
Update on evidence-based clinical application of sodium-glucose cotransporter inhibitors: Insight to uncommon cardiovascular disease scenarios in diabetes
Shibing Tao, Xi Lu, Zi‐Wei Ye, et al.
World Journal of Diabetes (2024) Vol. 15, Iss. 7, pp. 1461-1476
Open Access
HEART FAILURE AND CHRONIC KIDNEY DISEASE: PROGNOSIS AND THERAPEUTIC AND SURGICAL OPTIONS.
Thelma da Costa, Euripedes da Costa Machado, Layla Azevedo Alencastro Cupertino de Barros, et al.
Brazilian Journal of Implantology and Health Sciences (2024) Vol. 6, Iss. 8, pp. 1119-1132
Open Access
Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial
Nora Schwegel, Christoph Strohhofer, Ewald Kolesnik, et al.
Clinical Research in Cardiology (2024)
Open Access
Recent Advances Associated with Cardiometabolic Remodeling in Diabetes-induced Heart Failure
Gaurav Sharma, Shyam S. Chaurasia, Mark A. Carlson, et al.
AJP Heart and Circulatory Physiology (2024) Vol. 327, Iss. 6, pp. H1327-H1342
Closed Access
Page 1 - Next Page

Scroll to top